Tag: Araris Biotech

August 2026 was a busy month for the antibody-drug conjugate (ADC) field, with activity spanning the full arc of development. Highlights included early discovery partnerships, manufacturing alliances, a practice-changing phase 3 readout in lung cancer, and the first dosing of a novel Treg-depleting ADC.

Swiss oncology-focusing Araris Biotech and Japan's Chugai Pharmaceutical Co (a member of the Roche Group) have entered a Research Collaboration and Option to License Agreement under which Araris will use its proprietary linker-conjugation platform, AraLinQ™ to generate novel ADCs using antibodies against undisclosed targets provided by Chugai.

Araris Biotech and Chugai Pharmaceuticals to Develop Next-Generation Tailor-made ADCs

Swiss oncology-focused Araris Biotech, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, which is pioneering the development of next generation, proprietary antibody-drug conjugate (ADC)-linker technology, has entered a collaboration agreement with Japanese R&S driven specialty pharma Taiho Pharmaceutical Co.

Two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida, highlight late-breaking preclinical data from studies with an anti-Nectin-4 ADC and anti-HER2 ADC.